Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ULTRAM ER vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits serotonin and norepinephrine reuptake.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of moderate to moderately severe chronic pain in adults requiring around-the-clock treatment
Mild to moderate pain,Fever
100 mg orally once daily initially, titrate up to 100 mg twice daily as needed; maximum 200 mg/day.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
The terminal elimination half-life of tramadol is approximately 6.3 hours (range 5-9 hours), while its active metabolite M1 has a half-life of about 7.4 hours. Clinically, this supports dosing every 24 hours for the extended-release formulation.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Metabolized primarily via CYP2D6 and CYP3A4; O-desmethyltramadol (M1) is the active metabolite formed by CYP2D6; tramadol and metabolites undergo further conjugation.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal excretion of tramadol and its metabolites accounts for approximately 90% of total elimination. About 10% is excreted unchanged, 30% as O-desmethyltramadol (M1), and the remainder as other minor metabolites. Biliary/fecal excretion is minimal (<10%).
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 20% bound to plasma proteins, primarily albumin.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Volume of distribution is approximately 2.6-3.0 L/kg, indicating extensive tissue distribution beyond plasma volume.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral bioavailability of tramadol is approximately 75% after a single dose, increasing to 90-100% upon multiple dosing due to saturable first-pass metabolism. For ULTRAM ER, bioavailability is comparable to immediate-release formulations.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
GFR 30-80 m L/min: no adjustment; GFR <30 m L/min: avoid or extend dosing interval to 12 hours; not recommended in GFR <15 m L/min.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A or B: use with caution, consider reducing total daily dose by 50%; Child-Pugh Class C: contraindicated.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not recommended for use in pediatric patients <18 years due to risk of respiratory depression and lack of safety data.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Start at lowest dose (100 mg once daily); titrate cautiously; monitor for CNS and respiratory depression; consider reduced clearance in elderly.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion in children can be fatal; neonatal opioid withdrawal syndrome; risk of medication errors with other tramadol products; interactions with CNS depressants; serotonin syndrome; contraindicated in patients with significant respiratory depression; contraindicated in patients with acute or severe bronchial asthma; contraindicated in patients with known or suspected gastrointestinal obstruction; contraindicated in patients with previous hypersensitivity to tramadol.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Risk of respiratory depression; risk of serotonin syndrome with serotonergic drugs; risk of seizures especially in patients with epilepsy or risk factors; risk of adrenal insufficiency; risk of severe hypotension; risk of abuse and dependence; avoidance of abrupt discontinuation; use in renal or hepatic impairment; use in elderly; use in pregnancy and breastfeeding.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to tramadol or any formulation component; significant respiratory depression; acute or severe bronchial asthma in unmonitored settings; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days; use in children <12 years; use in children <18 years after tonsillectomy/adenoidectomy; use in patients with severe hepatic impairment.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid alcohol. No specific food restrictions; however, taking with food may reduce nausea. Grapefruit juice may increase tramadol levels; consider limiting grapefruit intake.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Pregnancy category C. First trimester: Limited data; avoid unless benefit outweighs risk due to potential neural tube defects. Second and third trimesters: Fetal dependence, neonatal withdrawal syndrome (seizures, irritability, respiratory depression) if used >7 days. Increased risk of preterm birth and low birth weight.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Ultram ER has an M/P ratio of 0.7-1.3. Small amounts excreted; can cause infant sedation and constipation. Use caution; monitor infant for drowsiness or feeding difficulties.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No established dose adjustments; pharmacokinetics may change in pregnancy (increased clearance, distribution volume). Use lowest effective dose; avoid sustained release if possible. Caution in third trimester due to risk of neonatal withdrawal.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
ULTRAM ER contains tramadol, an opioid agonist with SNRI properties. Do not crush or chew extended-release tablets; this can cause rapid release and fatal overdose. Use with caution in patients with seizure disorders or those taking SSRIs, SNRIs, MAOIs, or other drugs that lower seizure threshold. Avoid concurrent use with alcohol or CNS depressants. Monitor for serotonin syndrome when combined with serotonergic drugs. Do not discontinue abruptly after prolonged use; taper to avoid withdrawal symptoms. Not recommended for patients under 18. Crushing extended-release tablets is a safety hazard.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take ULTRAM ER exactly as prescribed, usually once daily. Swallow tablets whole; do not crush, chew, or break them.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) while taking this medication.,This medication has a risk of addiction, abuse, and misuse. Store securely and dispose of unused tablets properly.,Do not stop taking this medicine suddenly; withdrawal symptoms may occur. Follow your doctor's instructions for tapering.,Seek emergency medical help if you have trouble breathing, severe drowsiness, or slow heartbeat.,Inform your doctor if you have a history of seizures, head injury, or are taking antidepressants like MAOIs, SSRIs, or SNRIs.,ULTRAM ER may cause constipation, nausea, dizziness, or drowsiness. Increase fluid intake and fiber to prevent constipation.,Keep out of reach of children and pets. Accidental ingestion can be fatal.,Do not drive or operate heavy machinery until you know how ULTRAM ER affects you.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ULTRAM ER vs ACEPHEN, answered by our medical review team.
ULTRAM ER is a Opioid Analgesic that works by Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits serotonin and norepinephrine reuptake.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ULTRAM ER and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ULTRAM ER is: 100 mg orally once daily initially, titrate up to 100 mg twice daily as needed; maximum 200 mg/day.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ULTRAM ER and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ULTRAM ER is classified as Category C. Pregnancy category C. First trimester: Limited data; avoid unless benefit outweighs risk due to potential neural tube defects. Second and third trimesters: Fetal dependence, neonat. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.